Business Club December 23, 2009 For Fosun Pharma, the acquisition of Shenyang Hongqi and the presence of TB are an important part of its vision to achieve "global competitiveness."
Fosun Pharma, advocating "extensive expansion and endogenous growth," has been constantly moving.
Recently, Fosun Pharma announced in Shanghai that it will cooperate with Shenyang Hongqi Pharmaceutical Co., Ltd., a leading anti-tuberculosis enterprise in China, to jointly promote China's anti-tuberculosis drugs to the international market. It is reported that Fosun Pharma has acquired 70% equity of Hongqi Pharmaceutical through equity transfer, and the acquisition amount is 322 million yuan.
Chairman of Fosun Pharma, Chen Qiyu, said: "Through this cooperation, anti-tuberculosis drugs will become the second card for Fosun Pharmaceutical to enter the global pharmaceutical market after artesunate."
Fancy invisible champion
The data shows that China is one of the 22 countries with a high burden of tuberculosis in the world. At present, about 550 million people in China are infected with TB, the infection rate is 44.5%, which is 1/3 higher than the global average, and the number of patients is the second highest in the world, and 13 million cases of tuberculosis are added each year. According to reports from the World Health Organization, tuberculosis has seen a resurgence in the world in recent years.
Compared with the awareness of comprehensive pharmaceutical companies, Shenyang Hongqi was previously not well known, but in fact it is the stealth champion in the field of tuberculosis drugs. Shenyang Hongqi Pharmaceutical Co., Ltd., formerly Dong Pharm Group, was transformed into a private enterprise under the leadership of the current chairman Kang Shusen in 1998. After focusing on the field of tuberculosis drugs, it became China's largest R & D and production base for anti-tuberculosis drugs. According to public information, Shenyang Hongqi is the only three anti-tuberculosis drugs independently researched and developed by China (Ethylpyrazine rifampicin isoniazid tablets, ethylamine rifampicillide tablets, and Rifampin isoniazid tablets). Production companies and quality standards drafting units, and have independent intellectual property rights. It is the only domestic manufacturer of anti-tuberculosis compound preparations that meets WHO's recommended specifications for four-component (Ethylpyrazine, Isoxazole Tablets II), and is the WHO's globally recommended key anti-tuberculosis drug manufacturing company and the Ministry of Health of the People's Republic of China for tuberculosis control. Project "Pharmaceutical Designation Manufacturer.
"The anti-tuberculosis drugs are purchased through the government, and the red flag can win the bid in almost all government projects," said Duan Muhong, chairman of the China Flood Control Association.
Shenyang Hongqi has an absolute advantage in the field of tuberculosis, and has been focusing on finding Fosun in leading companies in the segmentation field. Both sides have negotiated for more than 3 years.
Designed to be international
With the resurgence of tuberculosis in the world in recent years, the WHO launched the Global Initiative to Stop TB Cooperation (2001) and proposed the goal of “The ultimate elimination of TB as a public health problem, creating a world free from TB†and setting a timetable: By 2015, the incidence of tuberculosis stopped growing and began to decline. Compared with the 1990 baseline, the prevalence of tuberculosis and mortality decreased by 50%; the public health problem of tuberculosis was eliminated by 2050. The relevant international agencies are making efforts to this end. The key point is: to ensure effective drug supply and management. According to statistics, the global market for the prevention and treatment of tuberculosis has exceeded 12 billion U.S. dollars.
Under this international situation, the Shenyang Red Flag, which has taken the lead in the domestic market, will undoubtedly need to extend its reach to the international community as quickly as possible, but at the same time it suffers from the bottleneck that “domestic enterprises generally lack international certification and international market operation experienceâ€. This has also become an important reason for its final acceptance of Fosun's “Olive Branchâ€. Fosun Pharma is the only supplier of WHO-GMP certification and PQ certification in Chinese pharmaceutical companies so far and has considerable experience in international operations.
"In order to graft Fosun Pharma's experience in anti-malarial drug-artesunate through WHO's PQ certification and access to international markets, we accelerated the advancement of GMP and PQ certifications for first-line and second-line drugs of Hongqi Pharmaceutical through the WHO and enter the world as soon as possible. In the market, Hongqi Pharmaceutical and Fosun Pharma decided to carry out strategic cooperation, said Kang Shusen, chairman of Shenyang Hongqi Pharmaceutical Co., Ltd.
Li Xianlin, senior vice president of Fosun Pharma and chairman of the Pharmaceutical Industry Management Committee, said: “Hongqi Pharmaceutical is already a leading domestic enterprise against tuberculosis, and Fosun Pharma will actively use its capital, talent, management, investment and acquisition, industrial integration and other aspects. Experience and strengths have helped Red Flag Pharmaceuticals develop global anti-tuberculosis medicine."
For Fosun Pharma, the acquisition of Shenyang Hongqi and its presence in the field of tuberculosis are an important part of its vision to achieve “global competitivenessâ€. After being involved in the field of anti-malaria and anti-tuberculosis, the anti-AIDS field will also be included in the expansion plan of Fosun Pharma. "After anti-malaria and anti-tuberculosis, we may take another step forward in the future and seek to expand in the field of anti-AIDS. We hope that we can make progress in the world's three most serious and severe infectious diseases and eventually become China's The world's leading pharmaceutical company." Chen Qiyu revealed.
Fosun Pharma, advocating "extensive expansion and endogenous growth," has been constantly moving.
Recently, Fosun Pharma announced in Shanghai that it will cooperate with Shenyang Hongqi Pharmaceutical Co., Ltd., a leading anti-tuberculosis enterprise in China, to jointly promote China's anti-tuberculosis drugs to the international market. It is reported that Fosun Pharma has acquired 70% equity of Hongqi Pharmaceutical through equity transfer, and the acquisition amount is 322 million yuan.
Chairman of Fosun Pharma, Chen Qiyu, said: "Through this cooperation, anti-tuberculosis drugs will become the second card for Fosun Pharmaceutical to enter the global pharmaceutical market after artesunate."
Fancy invisible champion
The data shows that China is one of the 22 countries with a high burden of tuberculosis in the world. At present, about 550 million people in China are infected with TB, the infection rate is 44.5%, which is 1/3 higher than the global average, and the number of patients is the second highest in the world, and 13 million cases of tuberculosis are added each year. According to reports from the World Health Organization, tuberculosis has seen a resurgence in the world in recent years.
Compared with the awareness of comprehensive pharmaceutical companies, Shenyang Hongqi was previously not well known, but in fact it is the stealth champion in the field of tuberculosis drugs. Shenyang Hongqi Pharmaceutical Co., Ltd., formerly Dong Pharm Group, was transformed into a private enterprise under the leadership of the current chairman Kang Shusen in 1998. After focusing on the field of tuberculosis drugs, it became China's largest R & D and production base for anti-tuberculosis drugs. According to public information, Shenyang Hongqi is the only three anti-tuberculosis drugs independently researched and developed by China (Ethylpyrazine rifampicin isoniazid tablets, ethylamine rifampicillide tablets, and Rifampin isoniazid tablets). Production companies and quality standards drafting units, and have independent intellectual property rights. It is the only domestic manufacturer of anti-tuberculosis compound preparations that meets WHO's recommended specifications for four-component (Ethylpyrazine, Isoxazole Tablets II), and is the WHO's globally recommended key anti-tuberculosis drug manufacturing company and the Ministry of Health of the People's Republic of China for tuberculosis control. Project "Pharmaceutical Designation Manufacturer.
"The anti-tuberculosis drugs are purchased through the government, and the red flag can win the bid in almost all government projects," said Duan Muhong, chairman of the China Flood Control Association.
Shenyang Hongqi has an absolute advantage in the field of tuberculosis, and has been focusing on finding Fosun in leading companies in the segmentation field. Both sides have negotiated for more than 3 years.
Designed to be international
With the resurgence of tuberculosis in the world in recent years, the WHO launched the Global Initiative to Stop TB Cooperation (2001) and proposed the goal of “The ultimate elimination of TB as a public health problem, creating a world free from TB†and setting a timetable: By 2015, the incidence of tuberculosis stopped growing and began to decline. Compared with the 1990 baseline, the prevalence of tuberculosis and mortality decreased by 50%; the public health problem of tuberculosis was eliminated by 2050. The relevant international agencies are making efforts to this end. The key point is: to ensure effective drug supply and management. According to statistics, the global market for the prevention and treatment of tuberculosis has exceeded 12 billion U.S. dollars.
Under this international situation, the Shenyang Red Flag, which has taken the lead in the domestic market, will undoubtedly need to extend its reach to the international community as quickly as possible, but at the same time it suffers from the bottleneck that “domestic enterprises generally lack international certification and international market operation experienceâ€. This has also become an important reason for its final acceptance of Fosun's “Olive Branchâ€. Fosun Pharma is the only supplier of WHO-GMP certification and PQ certification in Chinese pharmaceutical companies so far and has considerable experience in international operations.
"In order to graft Fosun Pharma's experience in anti-malarial drug-artesunate through WHO's PQ certification and access to international markets, we accelerated the advancement of GMP and PQ certifications for first-line and second-line drugs of Hongqi Pharmaceutical through the WHO and enter the world as soon as possible. In the market, Hongqi Pharmaceutical and Fosun Pharma decided to carry out strategic cooperation, said Kang Shusen, chairman of Shenyang Hongqi Pharmaceutical Co., Ltd.
Li Xianlin, senior vice president of Fosun Pharma and chairman of the Pharmaceutical Industry Management Committee, said: “Hongqi Pharmaceutical is already a leading domestic enterprise against tuberculosis, and Fosun Pharma will actively use its capital, talent, management, investment and acquisition, industrial integration and other aspects. Experience and strengths have helped Red Flag Pharmaceuticals develop global anti-tuberculosis medicine."
For Fosun Pharma, the acquisition of Shenyang Hongqi and its presence in the field of tuberculosis are an important part of its vision to achieve “global competitivenessâ€. After being involved in the field of anti-malaria and anti-tuberculosis, the anti-AIDS field will also be included in the expansion plan of Fosun Pharma. "After anti-malaria and anti-tuberculosis, we may take another step forward in the future and seek to expand in the field of anti-AIDS. We hope that we can make progress in the world's three most serious and severe infectious diseases and eventually become China's The world's leading pharmaceutical company." Chen Qiyu revealed.
Burdock Root,Burdock Plant,Burdock Oil,Organic Burdock Root
Yirun Agricultural Cooperative , https://www.yiruncn.com